Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
1.
PLoS One ; 16(10): e0258127, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34618852

RESUMO

Population risks for neonatal hyperbilirubinaemia (NH) vary. Knowledge of local risks permits interventions that may reduce the proportion becoming severe. Between January 2015 and May 2016, in a resource-limited setting on the Thailand-Myanmar border, neonates from 28 weeks' gestation were enrolled into a prospective birth cohort. Each neonate had total serum bilirubin measurements: scheduled (24, 48, 72 and 144 hours of life) and clinically indicated; and weekly follow up until 1 month of age. Risk factors for developing NH were evaluated using Cox proportional hazard mixed model. Of 1710 neonates, 22% (376) developed NH (83% preterm, 19% term). All neonates born <35 weeks, four in five born 35-37 weeks, and three in twenty born ≥38 weeks had NH, giving an overall incidence of 249 per 1000 livebirths [95%CI 225, 403]. Mortality from acute bilirubin encephalopathy was 10% (2/20) amongst the 5.3% (20/376) who reached the severe NH threshold. One-quarter (26.3%) of NH occurred within 24 hours. NH onset varied with gestational age: at a median [IQR] 24 hours [24, 30] for neonates born 37 weeks or prematurely vs 59 hours [48, 84] for neonates born ≥38 weeks. Risk factors for NH in the first week of life independent of gestational age were: neonatal G6PD deficiency, birth bruising, Sgaw Karen ethnicity, primigravidae, pre-eclampsia, and prolonged rupture of membranes. The genetic impact of G6PD deficiency on NH was partially interpreted by using the florescent spot test and further genotyping work is in progress. The risk of NH in Sgaw Karen refugees may be overlooked internationally as they are most likely regarded as Burmese in countries of resettlement. Given high levels of pathological jaundice in the first 24 hours and overall high NH burden, guidelines changes were implemented including preventive PT for all neonates <35 weeks and for those 35-37 weeks with risk factors.


Assuntos
Bilirrubina/sangue , Deficiência de Glucosefosfato Desidrogenase/sangue , Hiperbilirrubinemia Neonatal/sangue , Kernicterus/sangue , Estudos de Coortes , Estudos Epidemiológicos , Etnicidade/genética , Feminino , Genótipo , Deficiência de Glucosefosfato Desidrogenase/complicações , Deficiência de Glucosefosfato Desidrogenase/genética , Deficiência de Glucosefosfato Desidrogenase/mortalidade , Humanos , Hiperbilirrubinemia Neonatal/genética , Hiperbilirrubinemia Neonatal/mortalidade , Hiperbilirrubinemia Neonatal/patologia , Recém-Nascido , Kernicterus/complicações , Kernicterus/genética , Kernicterus/mortalidade , Masculino , Mianmar/epidemiologia , Pré-Eclâmpsia/sangue , Pré-Eclâmpsia/genética , Pré-Eclâmpsia/mortalidade , Gravidez , Modelos de Riscos Proporcionais , Estudos Prospectivos , Fatores de Risco , Tailândia/epidemiologia
3.
Neurology ; 95(11): e1471-e1478, 2020 09 15.
Artigo em Inglês | MEDLINE | ID: mdl-32651291

RESUMO

OBJECTIVE: To assess the risk of glucose-6-phosphate dehydrogenase (G6PD) on stroke prognosis, we compared outcomes between patients with stroke with and without G6PD deficiency. METHODS: The study recruited 1,251 patients with acute ischemic stroke. Patients were individually categorized into G6PD-deficiency and non-G6PD-deficiency groups according to G6PD activity upon admission. The primary endpoint was poor outcome at 3 months defined by a modified Rankin Scale (mRS) score ≥2 (including disability and death). Secondary outcomes included the overall mRS score at 3 months and in-hospital death and all death within 3 months. Logistic regression and Cox models, adjusted for potential confounders, were fitted to estimate the association of G6PD deficiency with the outcomes. RESULTS: Among 1,251 patients, 150 (12.0%) were G6PD-deficient. Patients with G6PD deficiency had higher proportions of large-artery atherosclerosis (odds ratio [OR] 1.53, 95% confidence interval [CI] 1.09-2.17) and stroke history (OR 1.93, 95% CI 1.26-2.90) compared to the non-G6PD-deficient group. The 2 groups differed significantly in the overall mRS score distribution (adjusted common OR 1.57, 95% CI 1.14-2.17). Patients with G6PD deficiency had higher rates of poor outcome at 3 months (adjusted OR 1.73, 95% CI 1.08-2.76; adjusted absolute risk increase 13.0%, 95% CI 2.4%-23.6%). The hazard ratio of in-hospital death for patients with G6PD-deficiency was 1.46 (95% CI 1.37-1.84). CONCLUSIONS: G6PD deficiency is associated with the risk of poor outcome at 3 months after ischemic stroke and may increase the risk of in-hospital death. These findings suggest the rationality of G6PD screening in patients with stroke.


Assuntos
Isquemia Encefálica/diagnóstico por imagem , Isquemia Encefálica/mortalidade , Deficiência de Glucosefosfato Desidrogenase/diagnóstico por imagem , Deficiência de Glucosefosfato Desidrogenase/mortalidade , Acidente Vascular Cerebral/diagnóstico por imagem , Acidente Vascular Cerebral/mortalidade , Idoso , Feminino , Seguimentos , Mortalidade Hospitalar/tendências , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
4.
J Stroke Cerebrovasc Dis ; 27(7): 2026-2031, 2018 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-29653805

RESUMO

BACKGROUND AND PURPOSE: No reports regarding the safety of thrombolysis in acute stroke patients with a G6PD deficiency have been published to date. Here we aimed to evaluate the safety of intravenous thrombolysis for G6PD-deficient stroke patients. METHODS: We enrolled each patient with acute ischemic stroke who arrived in our stroke unit within the therapeutic window and received systemic thrombolysis using recombinant tissue plasminogen activator (rt-PA), between January 2015 and March 2016. The primary clinical outcome was measured 3 months after treatment, and defined as a "good" outcome by a modified Rankin Scale (mRS) score of 0-2. Major safety outcomes were incidences of intracranial hemorrhage (ICH) or mortality at 90 days. RESULTS: A total of 96 individuals were analyzed, of which 20 patients were G6PD deficient. The rates of ICH after rt-PA treatment were 12% the in G6PD-deficient group versus 15% in G6PD non-deficient group, and the incidences of symptomatic intracranial hemorrhage were also similar between the G6PD-deficient and non-deficient cohorts. No hemolysis crisis occurred, and no significant difference in mortality rate was found between the 2 groups. The overall rate of a good outcome at 3 months after stroke in the whole cohort was 60%, whereas 50% of patients achieved an excellent outcome (mRS 0-1) in the G6PD-deficient cohort, and 42% in the G6PD non-deficient group. CONCLUSIONS: Thrombolytic therapy for patients with G6PD deficiency seems to pose a similar risk of ICH and clinical outcome to those with G6PD non-deficiency.


Assuntos
Isquemia Encefálica/tratamento farmacológico , Fibrinolíticos/administração & dosagem , Deficiência de Glucosefosfato Desidrogenase/complicações , Acidente Vascular Cerebral/tratamento farmacológico , Terapia Trombolítica , Ativador de Plasminogênio Tecidual/administração & dosagem , Administração Intravenosa , Adulto , Idoso , Isquemia Encefálica/complicações , Isquemia Encefálica/mortalidade , Feminino , Fibrinolíticos/efeitos adversos , Seguimentos , Deficiência de Glucosefosfato Desidrogenase/tratamento farmacológico , Deficiência de Glucosefosfato Desidrogenase/mortalidade , Humanos , Hemorragias Intracranianas/etiologia , Hemorragias Intracranianas/mortalidade , Masculino , Pessoa de Meia-Idade , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/efeitos adversos , Estudos Retrospectivos , Índice de Gravidade de Doença , Acidente Vascular Cerebral/complicações , Acidente Vascular Cerebral/mortalidade , Ativador de Plasminogênio Tecidual/efeitos adversos , Resultado do Tratamento
5.
Arch Iran Med ; 18(8): 502-7, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26265518

RESUMO

BACKGROUND: Hemoglobinopathies are known as the most common genetic disorders in Iran. The paper aims to provide global estimates of deaths and disability adjusted life years (DALYs) due to hemoglobinopathies in Iran by sex and age during 1990 to 2010 and describe the challenges due to limitations of the Global Burden of Disease Study 2010 (GBD 2010). METHODS: GBD 2010 estimates of the numbers of deaths and years of life lost (YLLs) due to premature mortality were calculated using the Cause of Death Ensemble model (CODEm). Years of life lost due to disability (YLDs) were computed by multiplication of prevalence, the disability weight for occurrence of sequelae, and the duration of symptoms. Prevalence was estimated through a systematic search of published and available unpublished data sources, with a Bayesian meta-regression model developed for GBD 2010. Disability weights were produced using collected data from population-based surveys. Uncertainty from all inputs was incorporated into the computations of DALYs using simulation methods. We aim to prepare and criticize the results of GBD 2010 and provide some recommendations for reaching better conclusions about the burden of hemoglobinopathies in Iran. RESULTS: Between 1990 and 2010, the overall deaths attributed to hemoglobinopathies decreased from 0.51% to 0.36% of total deaths, with the corresponding burden declining from 1% to 0.82% of total DALYs. There was a reduction in deaths and DALYs rates for all ages and the rates attributed to all ages followed the same pattern in Iranian men and women. The highest DALYs for hemoglobinopathies, thalassemia, sickle cell disorder, and glucose-6-phosphate dehydrogenase deficiency (G6PD-D) were found in those aged less than 5 years. The collective burden of all of these hemoglobin disorder was lower in 2010 than in 1990. CONCLUSION: Although the screening programs in Iran have been very successful in reducing the number of thalassemia patients between 1990 to 2010, in order to provide a better estimation of the burden of hemoglobin disorders, it is necessary to perform a national and sub-national study of hemoglobinopathies using multiple national and sub-national surveys.


Assuntos
Deficiência de Glucosefosfato Desidrogenase/mortalidade , Hemoglobinopatias/mortalidade , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Pessoas com Deficiência/estatística & dados numéricos , Feminino , Inquéritos Epidemiológicos , Humanos , Irã (Geográfico)/epidemiologia , Masculino , Pessoa de Meia-Idade , Adulto Jovem
6.
J Pediatr Hematol Oncol ; 32(1): 11-4, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-20051781

RESUMO

SUMMARY: This study analyzes the clinical features of glucose-6-phosphate dehydrogenase (G6PD) deficiency in infants with marked hyperbilirubinemia. We retrospectively assessed a cohort of 413 infants with peak total serum bilirubin (TSB) level >or=20 mg/dL from 1995 to 2007. The prevalence of G6PD deficiency was proportional to the level of peak TSB: 21.1% (81/383) in 20 mg/dL to 29.9 mg/dL, 45.5% (10/22) in 30 mg/dL to 39.9 mg/dL, and 100% (8/8) in >or=40 mg/dL. Male sex was more common in G6PD deficiency (75.8%). When compared with G6PD-normal infants, those with G6PD deficiency tended to have extreme hyperbilirubinemia (peak TSB level >or=25 mg/dL) and hemoglobin value<13 g/dL (P<0.001). Furthermore, mortality rate was significantly higher in G6PD-deficient infants (3.0%) than in the G6PD-normal counterparts (0.0%). Among 58 of the G6PD-deficient infants who were followed for more than 12 months, 4 developed the classic neurologic manifestations of kernicterus (6.6%). These findings show that G6PD deficiency is an important risk factor of extreme hyperbilirubinemia, death, and kernicterus.


Assuntos
Deficiência de Glucosefosfato Desidrogenase/complicações , Hiperbilirrubinemia Neonatal/etiologia , Estudos de Casos e Controles , Feminino , Seguimentos , Deficiência de Glucosefosfato Desidrogenase/epidemiologia , Deficiência de Glucosefosfato Desidrogenase/mortalidade , Humanos , Hiperbilirrubinemia Neonatal/epidemiologia , Recém-Nascido , Kernicterus/etiologia , Masculino , Prevalência , Estudos Retrospectivos , Fatores de Risco , Fatores Sexuais , Taxa de Sobrevida
8.
Int Arch Occup Environ Health ; 71(2): 148-50, 1998 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-9553792

RESUMO

OBJECTIVE: To discuss regulatory guidelines excluding subjects with erythrocyte glucose-6-phosphate dehydrogenase (G6PD) deficiency from lead-exposed jobs in the light of epidemiology findings on the mortality of these subjects. METHODS: Two mortality follow-up studies were conducted. The first comprised 1979 male subjects newly identified as G6PD-deficient during a 1981 screening of the G6PD polymorphism among the general population in Sardinia, Italy. The second comprised 1080 male workers employed in maintenance and production departments of a lead smelting plant, who were divided into two subcohorts by erythrocyte G6PD phenotype. RESULTS: As compared with the general male population, G6PD-deficient subjects had significantly fewer deaths than expected from ischemic heart disease (standardized mortality ratio (SMR) = 28; 95% CI 10-62), cerebrovascular diseases (SMR = 22; 95% CI 6-55), and liver cirrhosis (SMR = 12; 95% CI 0-66). Among lead smelters the standardized mortality rates from cardiovascular diseases and all cancers observed among the G6PD-deficient subcohort were lower than those seen among subjects with the wild-type G6PD. No death from disease of the blood and hematopoietic system was observed among G6PD-deficient subjects in these two follow-up studies. CONCLUSIONS: These studies did not provide evidence of hypersensitivity to lead hematotoxicity among G6PD-deficient individuals at exposure levels within the current standards. Provided that workplace exposure complies with current standards, the hypothetical benefit of excluding G6PD-deficient individuals from lead-exposed jobs should be weighted against the loss of personal abilities and the economic damage in a social environment with diffuse unemployment.


Assuntos
Deficiência de Glucosefosfato Desidrogenase/complicações , Deficiência de Glucosefosfato Desidrogenase/mortalidade , Chumbo/efeitos adversos , Exposição Ocupacional/normas , Saúde Ocupacional/legislação & jurisprudência , Adolescente , Adulto , Idoso , Definição da Elegibilidade , Emprego/normas , Estudos Epidemiológicos , Finlândia , Humanos , Hipersensibilidade , Masculino , Programas de Rastreamento , Pessoa de Meia-Idade
10.
Blood ; 91(2): 706-9, 1998 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-9427729

RESUMO

The objective of this study was to test the hypothesis of a lower mortality from cancer and cardiovascular diseases among men expressing glucose-6-phosphate dehydrogenase (G6PD) deficiency. We designed a mortality study based on death certificates from January 1, 1982 through December 31, 1992 in a cohort of G6PD-deficient men. Cohort members were 1,756 men, identified as expressing the G6PD-deficient phenotype during a 1981 population screening of the G6PD polymorphism. The setting was the island of Sardinia, Italy. Outcome measures were cause-specific standardized mortality ratios (SMRs), which were computed as 100 times the observed/expected ratio, with the general Sardinian male population as the reference. Deaths from all causes were significantly less than expected due to decreased SMRs for ischemic heart disease (SMR, 28; 95% confidence interval [CI], 10 to 62), cerebrovascular disease (SMR, 22; 95% CI, 6 to 55), and liver cirrhosis (SMR, 12; 95% CI, 0 to 66), which explained 95.6% of the deficit in total mortality. All cancer mortality was close to the expectation, with a significant increase in the SMR for non-Hodgkin's lymphoma (SMR, 545; 95% CI, 147 to 1,395). A decrease in mortality from cardiovascular diseases was one of the study hypotheses, based on an earlier human report and experimental evidence. However, selection bias is also a likely explanation. Further analytic studies are warranted to confirm whether subjects expressing the G6PD-deficient phenotype are protected against ischemic heart disease and cerebrovascular disease. This cohort study is consistent with more recent case-control studies in rejecting the hypothesis of a decreased cancer risk among G6PD-deficient subjects. The observed increase in mortality from non-Hodgkin's lymphoma and decrease in mortality from liver cirrhosis were not previously reported.


Assuntos
Deficiência de Glucosefosfato Desidrogenase/mortalidade , Adulto , Estudos de Coortes , Seguimentos , Deficiência de Glucosefosfato Desidrogenase/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Análise de Sobrevida
11.
Cancer Epidemiol Biomarkers Prev ; 5(3): 223-5, 1996 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-8833623

RESUMO

The mortality experience of 1345 male workers in a lead and zinc smelting plant was followed from 1973 to 1991. Information on the erythrocyte glucose-6-phosphate dehydrogenase (G6PD) phenotype was available for 1,222 (90.9%) cohort members, which provided the opportunity to compare the mortality experience of G6PD-deficient subjects to wild-type-G6PD coworkers with similar exposure to lead. A significant decrease in mortality was observed among the total cohort as well as among the subcohort of production and maintenance workers. Most deaths (27 of 31) and all cancer deaths occurred among production and maintenance workers. Lung cancer mortality was lower than expected. Two deaths from stomach cancer were observed versus 0.6 expected. Mortality from all causes and cancer mortality were lower among production and maintenance workers with the G6PD-deficient phenotype compared to coworkers with the wild-type phenotype. Although the low statistical power of this study prevents conclusive inference, lead smelter workers with the G6PD-deficient phenotype did not suffer adverse health outcomes in terms of mortality from all causes and cancer mortality compared to coworkers with the wild-type G6PD.


Assuntos
Indústria Química , Deficiência de Glucosefosfato Desidrogenase/mortalidade , Chumbo , Zinco , Adulto , Doenças Cardiovasculares/mortalidade , Estudos de Coortes , Eritrócitos/enzimologia , Seguimentos , Deficiência de Glucosefosfato Desidrogenase/genética , Efeito do Trabalhador Sadio , Humanos , Itália/epidemiologia , Neoplasias Pulmonares/mortalidade , Masculino , Neoplasias/mortalidade , Doenças Profissionais/mortalidade , Exposição Ocupacional , Avaliação de Resultados em Cuidados de Saúde , Fenótipo , Neoplasias Gástricas/mortalidade
12.
J Pediatr ; 126(1): 102-8, 1995 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-7815196

RESUMO

Our objective was to determine whether glucose-6-phosphate dehydrogenase (G6PD) deficiency and elevated carboxyhemoglobin (COHb) levels correlated with bilirubin-related morbidity and mortality rates. For this purpose, we studied 55 clinically jaundiced infants admitted to a rural mission hospital in southern Nigeria. Total serum bilirubin levels (range, 80 to 1016 mumol/L (4.7 to 59.4 mg/dl)) correlated with the percentage COHb concentrations (COHb = 0.45 + 0.08 Total serum bilirubin; r = 0.72). Infants were divided into two groups of equal size around the median COHb concentration (COHb range, 0.43% to 5.93% (median = 1.40%), with ambient carbon monoxide of 0.65 +/- 0.03 microL/L). The COHb levels > or = 1.40% were associated with the need for exchange transfusion (15/28, or 54%, vs 5/27, or 19%; p < 0.01) and with an increased incidence of clinical findings compatible with kernicterus (9/28, or 32%, vs 0/27, or 0%; p < 0.01). Mortality rate was 29% (8/29) among infants with higher COHb levels, and 7% (2/28) in those with lower levels (p = 0.08). Thirty-one percent (14/45) of the clinically jaundiced infants tested had G6PD deficiency. Thirty-six percent of the infants with G6PD deficiency died with presumed kernicterus, compared with only 3% (1/31) of the infants with a normal G6PD screening test result (p < 0.01). These data suggest that G6PD deficiency and increased bilirubin production, as indexed by COHb, are associated with jaundice-related morbidity and death in Nigerian infants.


Assuntos
Bilirrubina/sangue , Carboxihemoglobina/análise , Deficiência de Glucosefosfato Desidrogenase/sangue , Mortalidade Infantil , Icterícia/sangue , Transfusão de Sangue , Feminino , Deficiência de Glucosefosfato Desidrogenase/epidemiologia , Deficiência de Glucosefosfato Desidrogenase/mortalidade , Humanos , Recém-Nascido , Icterícia/complicações , Icterícia/terapia , Kernicterus/diagnóstico , Kernicterus/etiologia , Kernicterus/mortalidade , Masculino , Nigéria/epidemiologia
13.
Genetika ; 18(7): 1169-72, 1982 Jul.
Artigo em Russo | MEDLINE | ID: mdl-6214450

RESUMO

Viability of children in families in which one or both parents had glucose-6-phosphate dehydrogenase deficiency was studied. 159 couples from three districts of the Shekin region of the Azerbaijan SSR were examined. The data were obtained by the half-quality method of fluorescent spots. Four types of marriages were defined using the results of the screening programme. The number of pregnancies and their outcome were analyzed. Elimination of pregnancies in marriages where one or both parents were carriers for Gd- allele, was reliably increased in the antenatal period. This was established under conditions of the absence of selection for hetero- and hemizygotes for this allele in the districts examined. The highest value of elimination of pregnancies was noted in marriages in which both parents were Gd- allele carriers.


Assuntos
Alelos , Deficiência de Glucosefosfato Desidrogenase/genética , Heterozigoto , Malária/genética , Adulto , Azerbaijão , Feminino , Morte Fetal/epidemiologia , Morte Fetal/genética , Deficiência de Glucosefosfato Desidrogenase/mortalidade , Humanos , Recém-Nascido , Masculino , Gravidez
14.
N Engl J Med ; 300(18): 1001-5, 1979 May 03.
Artigo em Inglês | MEDLINE | ID: mdl-431593

RESUMO

To determine whether sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency influence the course and fatality rates of certain diseases requiring hospitalization, especially those associated with thrombotic phenomena, we conducted a co-operative study of 65,154 consecutively admitted, black male patients in 13 Veterans Administration hospitals. The overall frequency of sickle-cell trait was 7.8 per cent and of glucose-6-phosphate dehydrogenase dificiency 11.2 per cent. Both conditions were present in 0.9 per cent of those examined. There were regional, but no age-dependent, differences in the frequency of sickle-cell trait. Sickle-cell trait had no effect on average age at hospitalization or death, overall mortality, length of hospitalization on medical and surgical wards and frequency of any diagnosis, except essential hematuria and pulmonary embolism. Although statistically significant (P less than 0.001), the differences for the latter were small (1.5 per cent of all patients with normal hemoglobin and 2.2 per cent of patients with sickle-cell trait). Glucose-6-phosphate dehydrogenase deficiency had no adverse effect.


Assuntos
Anemia Falciforme/complicações , Deficiência de Glucosefosfato Desidrogenase/complicações , Traço Falciforme/complicações , Adulto , Fatores Etários , Idoso , População Negra , Angiopatias Diabéticas/complicações , Deficiência de Glucosefosfato Desidrogenase/epidemiologia , Deficiência de Glucosefosfato Desidrogenase/mortalidade , Hospitalização , Humanos , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/complicações , Embolia Pulmonar/complicações , Embolia Pulmonar/epidemiologia , Pielonefrite/complicações , Traço Falciforme/epidemiologia , Traço Falciforme/mortalidade , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...